Impact of interleukin-27 on replication of hepatitis C virus
Gaetano Scotto1, Adele Giammario1, Francesca Campanale1, Giovanna D’Addiego1, Vincenzina Fazio2
1Clinic of Infectious Diseases, University of Foggia, Italy; 2Clinical Chemistry Laboratory, Hospital of Foggia, Italy
Abstract: Recently, different interleukins have been associated with responses to PEGylated interferon and ribavirin and spontaneous clearance of acute hepatitis C virus (HCV) infection (interleukin [IL]-28B) or with the development of a novel immunotherapeutic strategy for HCV infection (IL-27). IL-27 is a helical cytokine belonging to the IL-6/IL-12 cytokine family with a broad range of anti-inflammatory properties. Some studies demonstrated that IL-27 stimulates hepatoma cells and hepatocytes by inducing a sustained signal transducer and activator of transcription (STAT1 and STAT3) activation. Moreover, IL-27 induces interferon-α-like responses including the induction of antiviral genes (ribonucleic acid-dependent protein kinase), oligoadenylate synthetase, and myxovirus protein. In this review we examine the research on IL-27 and its potential role in therapy for HCV, including the capability to inhibit replication of HCV.
Keywords: interleukin-27, hepatitis C virus, chronic liver disease, chronic hepatitis C infection
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]